173 related articles for article (PubMed ID: 38074669)
1. Construction of a prognostic 6-gene signature for breast cancer based on multi-omics and single-cell data.
Xing Z; Lin D; Hong Y; Ma Z; Jiang H; Lu Y; Sun J; Song J; Xie L; Yang M; Xie X; Wang T; Zhou H; Chen X; Wang X; Gao J
Front Oncol; 2023; 13():1186858. PubMed ID: 38074669
[TBL] [Abstract][Full Text] [Related]
2. Construction of an immune-related risk score signature for gastric cancer based on multi-omics data.
Wang Y; Huang W; Zheng S; Wang L; Zhang L; Pei X
Sci Rep; 2024 Jan; 14(1):1422. PubMed ID: 38228846
[TBL] [Abstract][Full Text] [Related]
3. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer.
Zheng J; Zhang YF; Han GH; Fan MY; Du MH; Zhang GC; Zhang B; Qiao J; Zhang SX; Cao JM
Adv Ther; 2023 Jan; 40(1):310-330. PubMed ID: 36316558
[TBL] [Abstract][Full Text] [Related]
5. Integrative multi-omics analyses unravel the immunological implication and prognostic significance of CXCL12 in breast cancer.
Gao ZJ; Fang Z; Yuan JP; Sun SR; Li B
Front Immunol; 2023; 14():1188351. PubMed ID: 37564657
[TBL] [Abstract][Full Text] [Related]
6. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
7. Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq.
Xu J; Qin S; Yi Y; Gao H; Liu X; Ma F; Guan M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077333
[TBL] [Abstract][Full Text] [Related]
8. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer.
Liu Z; Ding M; Qiu P; Pan K; Guo Q
Front Immunol; 2023; 14():1200282. PubMed ID: 37520534
[TBL] [Abstract][Full Text] [Related]
10. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Breast Cancer.
Yuan J; Duan F; Zhai W; Song C; Wang L; Xia W; Hua X; Yuan Z; Bi X; Huang J
Int J Womens Health; 2021; 13():1053-1064. PubMed ID: 34785957
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer.
Ren C; Tang X; Lan H
PeerJ; 2021; 9():e11377. PubMed ID: 33987034
[TBL] [Abstract][Full Text] [Related]
12. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response.
Cao J; Liang Y; Gu JJ; Huang Y; Wang B
Front Genet; 2022; 13():991162. PubMed ID: 36353118
[No Abstract] [Full Text] [Related]
13. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.
Gao Y; Wang X; Li S; Zhang Z; Li X; Lin F
Med Sci Monit; 2021 May; 27():e930025. PubMed ID: 34003815
[TBL] [Abstract][Full Text] [Related]
14. A 17-gene expression-based prognostic signature associated with the prognosis of patients with breast cancer: A STROBE-compliant study.
Qian JX; Yu M; Sun Z; Jiang AM; Long B
Medicine (Baltimore); 2020 Apr; 99(15):e19255. PubMed ID: 32282693
[TBL] [Abstract][Full Text] [Related]
15. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery.
Zou Y; Xie J; Zheng S; Liu W; Tang Y; Tian W; Deng X; Wu L; Zhang Y; Wong CW; Tan D; Liu Q; Xie X
Int J Surg; 2022 Nov; 107():106936. PubMed ID: 36341760
[TBL] [Abstract][Full Text] [Related]
16. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
17. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
18. Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.
Shen X; Zhong J; He J; Han J; Chen N
Front Immunol; 2022; 13():978092. PubMed ID: 36105819
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer.
Huang Z; Pan J; Wang H; Du X; Xu Y; Wang Z; Chen D
Front Cell Dev Biol; 2021; 9():657547. PubMed ID: 33928086
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a novel CNV-related prognostic signature predicting prognosis in patients with breast cancer.
Hu W; Li M; Zhang Q; Liu C; Wang X; Li J; Qiu S; Li L
J Ovarian Res; 2021 Aug; 14(1):103. PubMed ID: 34364397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
